Financhill
Buy
53

SHC Quote, Financials, Valuation and Earnings

Last price:
$13.59
Seasonality move :
24.9%
Day range:
$12.90 - $13.36
52-week range:
$10.71 - $17.44
Dividend yield:
0%
P/E ratio:
53.32x
P/S ratio:
3.38x
P/B ratio:
8.03x
Volume:
917.6K
Avg. volume:
1.6M
1-year change:
-19.84%
Market cap:
$3.8B
Revenue:
$1B
EPS (TTM):
$0.25

Analysts' Opinion

  • Consensus Rating
    Sotera Health has received a consensus rating of . The company's average rating is a based on 3 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $16.19, Sotera Health has an estimated upside of 21.44% from its current price of $13.33.
  • Price Target Downside
    According to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $13.33.

Fair Value

  • According to the consensus of 0 analysts, Sotera Health has 21.44% upside to fair value with a price target of $16.19 per share.

SHC vs. S&P 500

  • Over the past 5 trading days, Sotera Health has overperformed the S&P 500 by 0.87% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Sotera Health does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Sotera Health has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Sotera Health reported revenues of $285.5M.

Earnings Growth

  • Sotera Health earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sotera Health reported earnings per share of $0.06.
Enterprise value:
5.7B
EV / Invested capital:
2.11x
Price / LTM sales:
3.38x
EV / EBIT:
18.92x
EV / Revenue:
5.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
55.00x
Price / Operating cash flow:
36.61x
Enterprise value / EBITDA:
12.25x
Gross Profit (TTM):
$618M
Return On Assets:
2.29%
Net Income Margin (TTM):
6.32%
Return On Equity:
16.51%
Return On Invested Capital:
2.66%
Operating Margin:
28.2%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $993.3M $990.6M $1.1B $263.2M $285.5M
Gross Profit $549.2M $538.8M $618M $146M $158M
Operating Income $254.6M $232.8M $314.5M $76.1M $80.5M
EBITDA $404.8M -$52M $465M $79.3M $127.4M
Diluted EPS $0.44 -$1.10 $0.25 -$0.05 $0.06
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $308.5M $337.3M $420.7M $519.6M $563.6M
Total Assets $2.7B $2.7B $2.8B $3B $3.1B
Current Liabilities $144.7M $133.6M $140M $200.6M $195.5M
Total Liabilities $3.4B $2.2B $2.2B $2.7B $2.7B
Total Equity -$662M $525.8M $606.7M $377.5M $470.2M
Total Debt $2.9B $1.7B $1.7B $2.2B $2.2B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $242.4M -$158.9M $281.6M $41.8M $97.5M
Cash From Investing -$182.4M -$221.8M -$178M -$52M -$36.4M
Cash From Financing -$3.3M $469M -$47.8M -$3.5M -$2.7M
Free Cash Flow $90.5M -$380.8M $103.5M -$10.2M $61.1M
SHC
Sector
Market Cap
$3.8B
$45.6M
Price % of 52-Week High
76.43%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-19.84%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $13.21
200-day SMA
Sell
Level $13.46
Bollinger Bands (100)
Sell
Level 13.75 - 16.25
Chaikin Money Flow
Sell
Level -69.8M
20-day SMA
Buy
Level $13.17
Relative Strength Index (RSI14)
Sell
Level 45.47
ADX Line
Sell
Level 7.98
Williams %R
Neutral
Level -31.1321
50-day SMA
Sell
Level $14.39
MACD (12, 26)
Sell
Level -0.29
25-day Aroon Oscillator
Sell
Level -12
On Balance Volume
Sell
Level -5.8M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (1.4944)
Sell
CA Score (Annual)
Level (-1.6868)
Sell
Beneish M-Score (Annual)
Level (-1.9414)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.8573)
Buy
Piotroski F Score (Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.

Stock Forecast FAQ

In the current month, SHC has received 3 Buy ratings 4 Hold ratings, and 0 Sell ratings. The SHC average analyst price target in the past 3 months is $16.19.

  • Where Will Sotera Health Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Sotera Health share price will rise to $16.19 per share over the next 12 months.

  • What Do Analysts Say About Sotera Health?

    Analysts are divided on their view about Sotera Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sotera Health is a Sell and believe this share price will drop from its current level to $13.00.

  • What Is Sotera Health's Price Target?

    The price target for Sotera Health over the next 1-year time period is forecast to be $16.19 according to 0 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.

  • Is SHC A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Sotera Health is a . 0 of 0 analysts rate the stock a at this time.

  • How Can I Buy Shares Of SHC?

    You can purchase shares of Sotera Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sotera Health shares.

  • What Is The Sotera Health Share Price Today?

    Sotera Health was last trading at $13.59 per share. This represents the most recent stock quote for Sotera Health. Yesterday, Sotera Health closed at $13.33 per share.

  • How To Buy Sotera Health Stock Online?

    In order to purchase Sotera Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
73
PSIX alert for Dec 24

Power Solutions International [PSIX] is up 27.42% over the past day.

Sell
40
MSTR alert for Dec 24

MicroStrategy [MSTR] is up 8.07% over the past day.

Sell
26
NUTX alert for Dec 24

Nutex Health [NUTX] is down 1.39% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock